美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Tvardi Therapeutics Inc

1.87

+0.03501.91%

盤後：1.84-0.0300-1.60%19:57 EDT

成交量：11.64萬

成交額：22.13萬

市值：2,494.37萬

市盈率：-0.67

高：1.94

開：1.83

低：1.83

收：1.84

52周最高：43.65

52周最低：1.50

股本：1,333.89萬

流通股本：567.13萬

量比：1.14

換手率：2.05%

股息：- -

股息率：- -

每股收益(TTM):-2.7737

每股收益(LYR):-3.2600

淨資產收益率：-126.19%

總資產收益率：-55.51%

市淨率：2.98

市盈率(LYR):-0.57

資料載入中...

總覽公司新聞公告

美國研究綜述-應用材料公司、CME集團、納斯達克

美國研究綜述-應用材料公司、CME集團、納斯達克

Piper Sandler將Tvardi Therapeutics評級上調至「增持」，目標價大幅提升至13美元

Tvardi股價上漲，其口腔炎症藥物在早期臨床試驗中展現出良好前景

Tvardi Therapeutics旗下Tti-109展現快速轉化與高達60%的Stat3驅動免疫細胞減少

Tvardi Therapeutics Tti-109 I期研究證實前藥設計、耐受性改善及Stat3靶點參與的藥效學證據

Tvardi Therapeutics 計劃推進Tti-109用於STAT3驅動皮膚病及胃腸道疾病——需額外資金支持

Tvardi Therapeutics Inc：Tti-101治療肝細胞癌二期試驗頂線數據預計2026年下半年公布

Tvardi Therapeutics Inc：現金儲備預計足以支撐運營至臨床數據公布期及2026年第四季度

Tvardi Therapeutics Inc將於2026年6月公布Tti-109關鍵數據及臨床開發戰略

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/TVRD/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"TVRD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVRD\",,,,,undefined,":{"symbol":"TVRD","market":"US","secType":"STK","nameCN":"Tvardi Therapeutics Inc","latestPrice":1.87,"timestamp":1789156800000,"preClose":1.835,"halted":0,"volume":116425,"hourTrading":{"tag":"盘后","latestPrice":1.84,"preClose":1.87,"latestTime":"19:57 EDT","volume":1034,"amount":1916.44,"timestamp":1789171024977,"change":-0.03,"changeRate":-0.016043,"amplitude":0.016043},"delay":0,"changeRate":0.019073569482288905,"floatShares":5671300,"shares":13338900,"eps":-2.773725,"marketStatus":"未開盤","change":0.035,"latestTime":"09-11 16:00:00 EDT","open":1.83,"high":1.94,"low":1.83,"amount":221284.876055,"amplitude":0.059946,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.773725,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":0,"adr":0,"listingDate":1391144400000,"exchange":"NASDAQ","adjPreClose":1.835,"postHourTrading":{"tag":"盘后","latestPrice":1.84,"preClose":1.87,"latestTime":"19:57 EDT","volume":1034,"amount":1916.44,"timestamp":1789171024977,"change":-0.03,"changeRate":-0.016043,"amplitude":0.016043},"volumeRatio":1.1395421656855744,"impliedVol":2.0171,"impliedVolPercentile":0.6614},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVRD\",,,,,undefined,":{"symbol":"TVRD","floatShares":5671300,"roa":"-55.51%","roe":"-126.19%","lyrEps":-3.259999,"volumeRatio":1.1395421656855744,"shares":13338900,"dividePrice":0,"high":1.94,"amplitude":0.059946,"preClose":1.835,"low":1.83,"week52Low":1.5,"pbRate":"2.98","week52High":43.65,"institutionHeld":0,"latestPrice":1.87,"eps":-2.773725,"divideRate":0,"volume":116425,"delay":0,"ttmEps":-2.773725,"open":1.83,"prevYearClose":4.3,"prevWeekClose":1.91,"prevMonthClose":1.8,"prevQuarterClose":1.9,"fiveDayClose":1.85,"twentyDayClose":1.77,"sixtyDayClose":2.63},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TVRD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-14","symbol":"TVRD","fiscalQuarterEnding":"2026/06","expectedEps":-0.65,"name":null,"time":"盤前","type":"earning","dateTimestamp":1786680000000,"reportTimeType":"pre","actualEps":-0.69},{"market":"US","date":"2026-05-08","symbol":"TVRD","fiscalQuarterEnding":"2026/03","expectedEps":-0.65,"name":null,"time":"盤前","type":"earning","dateTimestamp":1778212800000,"reportTimeType":"pre","actualEps":-0.73},{"market":"US","date":"2026-03-31","symbol":"TVRD","fiscalQuarterEnding":"2025/12","expectedEps":-0.55,"name":null,"time":"盤後","type":"earning","dateTimestamp":1774929600000,"reportTimeType":"post","actualEps":-0.78},{"market":"US","date":"2025-11-13","symbol":"TVRD","fiscalQuarterEnding":"2025/09","expectedEps":-0.83,"name":null,"time":"盤後","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-0.59},{"market":"US","date":"2025-08-14","symbol":"TVRD","fiscalQuarterEnding":"2025/06","expectedEps":-0.51,"name":null,"time":"盤後","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":1}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TVRD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TVRD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2222,"buy":0.5556,"hold":0.1111,"sell":0.1111,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5556,"analysts":9,"updateTime":1788926400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TVRD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TVRD","date":"2026-09-11","current":-0.674184,"percent":0.953901,"low":-17.054928,"twenty":-2.728471,"median":-1.658378,"eighty":-1.472643,"high":-0.658706,"avg":-3.555343,"sd":4.24455,"marketCap":24476960},"quantilePoints":[{"date":"2025-08-01","current":-6.984237,"twenty":-7.018674,"median":-6.984237,"eighty":-6.867475,"marketCap":242869870},{"date":"2025-08-08","current":-6.220168,"twenty":-7.05634,"median":-6.986928,"eighty":-6.651705,"marketCap":216300131},{"date":"2025-08-15","current":-6.400424,"twenty":-7.003609,"median":-6.690985,"eighty":-6.397734,"marketCap":222568344},{"date":"2025-08-22","current":-10.573024,"twenty":-9.576632,"median":-6.986928,"eighty":-6.42948,"marketCap":249861702},{"date":"2025-08-29","current":-12.013447,"twenty":-10.759129,"median":-7.048807,"eighty":-6.480866,"marketCap":283901784},{"date":"2025-09-05","current":-12.078921,"twenty":-11.588463,"median":-7.134899,"eighty":-6.493511,"marketCap":285449060},{"date":"2025-09-12","current":-14.047103,"twenty":-11.928926,"median":-9.803211,"eighty":-6.612426,"marketCap":331961128},{"date":"2025-09-19","current":-15.372451,"twenty":-12.457478,"median":-10.666275,"eighty":-6.823352,"marketCap":363281754},{"date":"2025-09-26","current":-14.606606,"twenty":-13.432046,"median":-11.499578,"eighty":-6.955181,"marketCap":345183308},{"date":"2025-10-03","current":-14.82882,"twenty":-14.620891,"median":-11.737664,"eighty":-6.987466,"marketCap":350434671},{"date":"2025-10-10","current":-17.054928,"twenty":-14.850248,"median":-11.943013,"eighty":-6.991233,"marketCap":403042070},{"date":"2025-10-17","current":-2.571334,"twenty":-14.850248,"median":-11.769409,"eighty":-6.823352,"marketCap":60765765},{"date":"2025-10-24","current":-2.047544,"twenty":-14.833582,"median":-11.58886,"eighty":-6.422216,"marketCap":48387554},{"date":"2025-10-31","current":-1.849138,"twenty":-14.74787,"median":-11.130543,"eighty":-4.843171,"marketCap":43698837},{"date":"2025-11-07","current":-1.563435,"twenty":-14.662953,"median":-10.195062,"eighty":-2.595143,"marketCap":36947086},{"date":"2025-11-14","current":-1.631573,"twenty":-14.620891,"median":-9.523459,"eighty":-2.06421,"marketCap":38557323},{"date":"2025-11-21","current":-1.515552,"twenty":-14.489944,"median":-7.06764,"eighty":-1.887232,"marketCap":35836734},{"date":"2025-11-28","current":-1.634574,"twenty":-14.266143,"median":-6.990963,"eighty":-1.811838,"marketCap":38651137},{"date":"2025-12-05","current":-1.658378,"twenty":-13.805842,"median":-6.911597,"eighty":-1.667399,"marketCap":39214017},{"date":"2025-12-12","current":-1.781368,"twenty":-13.436014,"median":-6.493242,"eighty":-1.662637,"marketCap":42122234},{"date":"2025-12-19","current":-1.543324,"twenty":-13.412999,"median":-6.400424,"eighty":-1.660082,"marketCap":36493428},{"date":"2025-12-26","current":-1.5949,"twenty":-13.32332,"median":-6.349307,"eighty":-1.639335,"marketCap":37713002},{"date":"2026-01-02","current":-1.705987,"twenty":-13.031267,"median":-2.777676,"eighty":-1.642509,"marketCap":40339779},{"date":"2026-01-09","current":-1.678216,"twenty":-12.62652,"median":-2.62292,"eighty":-1.634574,"marketCap":39683085},{"date":"2026-01-16","current":-1.789303,"twenty":-12.344784,"median":-2.448323,"eighty":-1.634574,"marketCap":42309861},{"date":"2026-01-23","current":-1.91626,"twenty":-12.181298,"median":-2.07532,"eighty":-1.634574,"marketCap":45311891},{"date":"2026-01-30","current":-1.547291,"twenty":-12.091222,"median":-1.95231,"eighty":-1.634574,"marketCap":36587241},{"date":"2026-02-06","current":-1.408431,"twenty":-12.026542,"median":-1.896756,"eighty":-1.617117,"marketCap":33303771},{"date":"2026-02-13","current":-1.475877,"twenty":-11.900753,"median":-1.8627,"eighty":-1.598129,"marketCap":34898599},{"date":"2026-02-20","current":-1.424301,"twenty":-11.810677,"median":-1.847154,"eighty":-1.590139,"marketCap":33679024},{"date":"2026-02-27","current":-1.606802,"twenty":-11.750362,"median":-1.836912,"eighty":-1.577443,"marketCap":37994443},{"date":"2026-03-06","current":-1.5949,"twenty":-11.649572,"median":-1.807157,"eighty":-1.573476,"marketCap":37713002},{"date":"2026-03-13","current":-1.458024,"twenty":-11.588463,"median":-1.789617,"eighty":-1.565651,"marketCap":34476439},{"date":"2026-03-20","current":-1.460008,"twenty":-11.482118,"median":-1.781368,"eighty":-1.559193,"marketCap":34523345},{"date":"2026-03-27","current":-1.321148,"twenty":-11.243237,"median":-1.741999,"eighty":-1.553639,"marketCap":31239875},{"date":"2026-04-02","current":-1.545187,"twenty":-10.944836,"median":-1.71789,"eighty":-1.546029,"marketCap":28144032},{"date":"2026-04-10","current":-1.524584,"twenty":-10.628975,"median":-1.704004,"eighty":-1.543324,"marketCap":27768778},{"date":"2026-04-17","current":-1.6585,"twenty":-10.270654,"median":-1.682478,"eighty":-1.543324,"marketCap":30207927},{"date":"2026-04-24","current":-1.550337,"twenty":-9.805989,"median":-1.678216,"eighty":-1.544069,"marketCap":28237845},{"date":"2026-05-01","current":-1.622446,"twenty":-9.682977,"median":-1.674248,"eighty":-1.546029,"marketCap":29551233},{"date":"2026-05-08","current":-2.168412,"twenty":-8.568035,"median":-1.676379,"eighty":-1.548509,"marketCap":39495458},{"date":"2026-05-15","current":-2.406252,"twenty":-7.115528,"median":-1.682478,"eighty":-1.550705,"marketCap":37150122},{"date":"2026-05-22","current":-2.181425,"twenty":-7.071406,"median":-1.707971,"eighty":-1.552845,"marketCap":33679024},{"date":"2026-05-29","current":-2.120661,"twenty":-7.037507,"median":-1.719873,"eighty":-1.555226,"marketCap":32740890},{"date":"2026-06-05","current":-1.871529,"twenty":-6.991771,"median":-1.746061,"eighty":-1.555226,"marketCap":28894539},{"date":"2026-06-12","current":-1.646703,"twenty":-6.988542,"median":-1.736886,"eighty":-1.555278,"marketCap":25423442},{"date":"2026-06-18","current":-1.56771,"twenty":-6.984237,"median":-1.719873,"eighty":-1.555488,"marketCap":24203867},{"date":"2026-06-26","current":-1.434029,"twenty":-6.911597,"median":-1.705987,"eighty":-1.555226,"marketCap":22139971},{"date":"2026-07-02","current":-1.184897,"twenty":-6.735107,"median":-1.689237,"eighty":-1.549728,"marketCap":18293620},{"date":"2026-07-10","current":-2.30903,"twenty":-6.533867,"median":-1.695629,"eighty":-1.54687,"marketCap":35649107},{"date":"2026-07-17","current":-1.871529,"twenty":-6.492435,"median":-1.709955,"eighty":-1.549728,"marketCap":28894539},{"date":"2026-07-24","current":-1.555557,"twenty":-6.447775,"median":-1.713922,"eighty":-1.551074,"marketCap":24016240},{"date":"2026-07-31","current":-1.276043,"twenty":-6.414952,"median":-1.704004,"eighty":-1.544474,"marketCap":19700822},{"date":"2026-08-07","current":-1.124133,"twenty":-6.392353,"median":-1.682478,"eighty":-1.541737,"marketCap":17355486},{"date":"2026-08-14","current":-1.075522,"twenty":-6.364373,"median":-1.67765,"eighty":-1.526306,"marketCap":16604978},{"date":"2026-08-21","current":-0.658706,"twenty":-6.271824,"median":-1.674248,"eighty":-1.509204,"marketCap":17167859},{"date":"2026-08-28","current":-0.921233,"twenty":-4.310985,"median":-1.663144,"eighty":-1.491321,"marketCap":24010097},{"date":"2026-09-04","current":-0.946823,"twenty":-2.881884,"median":-1.6585,"eighty":-1.478258,"marketCap":24677044},{"date":"2026-09-11","current":-0.939146,"twenty":-2.728471,"median":-1.658378,"eighty":-1.472643,"marketCap":24476960}],"updateTime":1789366105772},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TVRD\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2650941048","title":"美國研究綜述-應用材料公司、CME集團、納斯達克","url":"https://stock-news.laohu8.com/highlight/detail?id=2650941048","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650941048?lang=zh_tw&edition=fundamental","pubTime":"2026-07-09 15:29","pubTimestamp":1783582192,"startTime":"0","endTime":"0","summary":"美国研究综述-应用材料公司、CME集团、纳斯达克路透7月9日-周四，华尔街证券分析师调整了多家在美国上市公司的评级和目标股价，其中包括应用材料公司、CME集团和纳斯达克。股票条目按字母顺序排列。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nL4S43B0L6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ICHR","CZR","CL","CFFN","MTZ","PKG","TW","EPAM","TINY","LW","ICE","AMAT","CART","WAT","NDAQ","AX","CME","LVS","VIRT","LEVI","MGM","NTRA","TVRD","MKTX","RRR","HSY","BANR","AVAV","FHB","COST","FCNCA","FDIG","KLAC","LSEG.UK","COIN","CPF","WYNN","BLLN","PLNT","AA","RWT","TBBK","PRM","LRCX","ABBV","BOH","EXLS","TECH","PENN","CECO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650094101","title":"美國研究綜述-應用材料公司、CME集團、納斯達克","url":"https://stock-news.laohu8.com/highlight/detail?id=2650094101","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650094101?lang=zh_tw&edition=fundamental","pubTime":"2026-07-09 15:29","pubTimestamp":1783582192,"startTime":"0","endTime":"0","summary":"美国研究综述-应用材料公司、CME集团、纳斯达克路透7月9日-周四，华尔街证券分析师调整了多家在美国上市公司的评级和目标股价，其中包括应用材料公司、CME集团和纳斯达克。股票条目按字母顺序排列。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nL4T43B0L6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FHLC","LEVI","ICE","AMAT","ICHR","TW","MGM","AX","NDAQ","PLNT","VIRT","FCNCA","CECO","EPAM","TVRD","WYNN","COIN","RWT","NTRA","MKTX","ABBV","BANR","HSY","LRCX","CL","LSEG.UK","LW","CME","FHB","PENN","BLLN","AA","TECH","CFFN","MTZ","WAT","LVS","CZR","EXLS","RRR","CART","PKG","COST","CPF","PRM","WUGI","KLAC","AVAV","TBBK","BOH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182444367","title":"Piper Sandler將Tvardi Therapeutics評級上調至「增持」，目標價大幅提升至13美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1182444367","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182444367?lang=zh_tw&edition=fundamental","pubTime":"2026-07-09 12:01","pubTimestamp":1783569678,"startTime":"0","endTime":"0","summary":"Piper Sandler发布最新研究报告，将生物制药公司Tvardi Therapeutics Inc的股票评级从“中性”显著上调至“增持”。与此同时，该机构大幅提高了其目标价，从此前的3美元跃升至13美元，显示出对公司未来发展前景的强烈信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVRD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649982699","title":"Tvardi股價上漲，其口腔炎症藥物在早期臨床試驗中展現出良好前景","url":"https://stock-news.laohu8.com/highlight/detail?id=2649982699","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649982699?lang=zh_tw&edition=fundamental","pubTime":"2026-07-07 19:48","pubTimestamp":1783424932,"startTime":"0","endTime":"0","summary":"BUZZ-Tvardi股价上涨，其口腔炎症药物在早期临床试验中展现出良好前景7月7日-** 药物开发商Tvardi Therapeutics（TVRD.O）的股价在盘前交易中上涨2%，至2.03美元** 该公司表示，其口服实验性药物TTI-109在早期研究中展现出的效果，与此前针对STAT3的药物TTI-101相当** 称TTI-109正在开发中，用于治疗与STAT3蛋白相关的炎症及异常细胞增殖所","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nL4T4390ZO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVRD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157277204","title":"Tvardi Therapeutics旗下Tti-109展現快速轉化與高達60%的Stat3驅動免疫細胞減少","url":"https://stock-news.laohu8.com/highlight/detail?id=1157277204","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157277204?lang=zh_tw&edition=fundamental","pubTime":"2026-07-07 19:05","pubTimestamp":1783422349,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics公司宣布，其候选药物Tti-109在临床前研究中表现出快速转化能力，并能够将Stat3驱动的免疫细胞数量减少高达60%。这一数据凸显了该药物在调节关键免疫信号通路方面的潜在效力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVRD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121974132","title":"Tvardi Therapeutics Tti-109 I期研究證實前藥設計、耐受性改善及Stat3靶點參與的藥效學證據","url":"https://stock-news.laohu8.com/highlight/detail?id=1121974132","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121974132?lang=zh_tw&edition=fundamental","pubTime":"2026-07-07 19:05","pubTimestamp":1783422322,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics公司近日公布了其候选药物Tti-109的I期临床研究数据。该数据有力地证实了其前体药物设计的合理性，同时显示出良好的耐受性改善，并提供了Stat3靶点参与的药效学证据。此外，在患者样本中观察到的药效学变化，为Stat3这一关键信号通路被有效抑制提供了直接证据。Stat3蛋白在多种肿瘤的发生与发展中扮演着核心角色，是肿瘤治疗领域备受关注的热门靶点。此次I期研究的积极结果，为Tti-109后续的临床开发奠定了重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVRD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121049283","title":"Tvardi Therapeutics 計劃推進Tti-109用於STAT3驅動皮膚病及胃腸道疾病——需額外資金支持","url":"https://stock-news.laohu8.com/highlight/detail?id=1121049283","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121049283?lang=zh_tw&edition=fundamental","pubTime":"2026-07-07 19:04","pubTimestamp":1783422284,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics Inc 宣布，计划将其候选药物Tti-109的开发重点，拓展至由STAT3信号通路驱动的皮肤病和胃肠道疾病领域。然而，这一战略推进的实施，将取决于公司能否成功获得必要的额外资金。Tti-109旨在靶向并抑制STAT3的活性，从而可能为这些难治性疾病提供新的治疗选择。公司表示，新的开发计划将基于Tti-109已有的临床前数据及其作用机制的科学依据。此举标志着Tvardi在探索其核心资产Tti-109治疗潜力方面，迈出了战略性的一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVRD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113723798","title":"Tvardi Therapeutics Inc：Tti-101治療肝細胞癌二期試驗頂線數據預計2026年下半年公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1113723798","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113723798?lang=zh_tw&edition=fundamental","pubTime":"2026-05-08 19:10","pubTimestamp":1778238637,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics Inc宣布，其核心候选药物Tti-101在肝细胞癌（HCC）患者中进行的二期临床试验，目前进展顺利。公司确认，该项研究的关键顶线数据仍按计划将于2026年下半年揭晓。\n这一重要里程碑的推进，标志着Tvardi公司在开发针对STAT3信号通路的新型口服小分子抑制剂方面取得了持续进展。Tti-101作为一种潜在的突破性疗法，旨在直接靶向STAT3，该靶点在多种实体瘤的生长和存活中扮演着关键角色。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVRD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165971805","title":"Tvardi Therapeutics Inc：現金儲備預計足以支撐運營至臨床數據公布期及2026年第四季度","url":"https://stock-news.laohu8.com/highlight/detail?id=1165971805","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165971805?lang=zh_tw&edition=fundamental","pubTime":"2026-05-08 19:10","pubTimestamp":1778238631,"startTime":"0","endTime":"0","summary":"生物制药公司Tvardi Therapeutics Inc近日宣布，其现有资金储备预计可充分支持公司运营至关键临床试验数据公布阶段，并持续维持至2026年第四季度。这一财务规划为公司在肿瘤治疗领域核心药物的临床开发提供了稳定保障。随着临床研究进入关键阶段，投资者可重点关注该公司在实体瘤和血液恶性肿瘤治疗领域的数据更新。稳定的现金储备为Tvardi Therapeutics在竞争激烈的生物科技赛道中提供了独特的续航优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVRD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178271385","title":"Tvardi Therapeutics Inc將於2026年6月公布Tti-109關鍵數據及臨床開發戰略","url":"https://stock-news.laohu8.com/highlight/detail?id=1178271385","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178271385?lang=zh_tw&edition=fundamental","pubTime":"2026-05-08 19:10","pubTimestamp":1778238625,"startTime":"0","endTime":"0","summary":"生物制药公司Tvardi Therapeutics Inc近日透露，其核心候选药物Tti-109的关键临床试验数据以及后续临床开发战略，预计将在2026年6月正式对外公布。\n此次即将披露的顶线数据备受业界关注，其结果将直接影响该药物未来的研发路径与商业化前景。公司计划基于这些数据制定明确的临床推进策略，为后续研究阶段提供清晰方向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVRD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":10,"code":"91000000","status":"200"}]}}